利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

97 条记录 (耗时 0.083 秒)

    Turing test based user authentication and user presence verification system, device, and method
    4.
    发明授权
    Turing test based user authentication and user presence verification system, device, and method 有权
    基于图灵测试的用户认证和用户存在验证系统，设备和方法

    公开(公告)号：US09081947B2

    公开(公告)日：2015-07-14

    申请号：US13976918

    申请日：2011-12-27

    申请人： Prashant Dewan ,  David M. Durham ,  Ling Huang ,  Karanvir S. Grewal ,  Xiaozhu Kang

    发明人： Prashant Dewan ,  David M. Durham ,  Ling Huang ,  Karanvir S. Grewal ,  Xiaozhu Kang

    IPC分类号： G06F21/32 ,  G06K9/78 ,  G06K9/00

    CPC分类号： G06F21/32 ,  G06K9/00288 ,  G06K9/00899

    摘要： A password-less method for authenticating a user includes capturing one or more images of a face of the user and comparing the one or more images with a previously collected face template. Randomly selected colored light and randomized blinking patterns are used to capture the images of the user. Such captured images are compared to previously collected face templates, thereby thwarting spoof attacks. A secret image, known only to the user and the device, is moved from one area of the display to another randomly selected area, using the movements of the user's head or face, thereby providing a Turing based challenge. Protected audio video path (PAVP) enabled devices and components are used to protect the challenge from malware attacks.

    摘要翻译： 用于认证用户的无密码方法包括捕获用户的脸部的一个或多个图像并将一个或多个图像与先前收集的面部模板进行比较。 随机选择的彩色光和随机闪烁图案用于捕获用户的图像。 将这样的拍摄图像与先前收集的面部模板进行比较，从而阻止欺骗攻击。 使用用户和设备已知的秘密图像使用用户头部或脸部的移动从显示器的一个区域移动到另一个随机选择的区域，从而提供基于图灵的挑战。 受保护的音频视频路径（PAVP）启用的设备和组件用于保护挑战免受恶意软件攻击。

    FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
    5.
    发明申请
    FcgammaRIIB-Specific Antibodies and Methods of Use Thereof 审中-公开
    FcgammaRIIB特异性抗体及其使用方法

    公开(公告)号：US20150023964A1

    公开(公告)日：2015-01-22

    申请号：US14331360

    申请日：2014-07-15

    申请人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    发明人： Leslie S. Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： C07K16/28 ,  A61K45/06 ,  A61K39/395

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than the antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    摘要翻译： 本发明涉及以比抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。 本发明还提供抗FcγRIIB抗体或其抗原结合片段作为治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞恶性肿瘤的单一药物治疗的用途 细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。 本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。

    Humanized FcγRIIB-specific antibodies and methods of use thereof
    6.
    发明授权
    Humanized FcγRIIB-specific antibodies and methods of use thereof 有权
    人源化FcγRIIB特异性抗体及其使用方法

    公开(公告)号：US08216579B2

    公开(公告)日：2012-07-10

    申请号：US12785117

    申请日：2010-05-21

    申请人： Leslie S. Johnson ,  Ling Huang

    发明人： Leslie S. Johnson ,  Ling Huang

    IPC分类号： A61K39/395

    CPC分类号： A61K39/39 ,  A61K2039/505 ,  A61K2039/55516 ,  C07K16/283 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/52 ,  G01N33/564 ,  G01N33/6893 ,  G01N2800/24

    摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.

    摘要翻译： 本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。 本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。 本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。 本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。 本发明包括治疗自身免疫性疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。

    Identification and engineering of antibodies with variant Fc regions and methods of using same
    8.
    发明授权
    Identification and engineering of antibodies with variant Fc regions and methods of using same 有权
    具有变体Fc区的抗体的鉴定和工程及其使用方法

    公开(公告)号：US07960512B2

    公开(公告)日：2011-06-14

    申请号：US10902588

    申请日：2004-07-28

    申请人： Jeffrey Stavenhagen ,  Sujata Vijh ,  Christopher Rankin ,  Sergey Gorlatov ,  Ling Huang

    发明人： Jeffrey Stavenhagen ,  Sujata Vijh ,  Christopher Rankin ,  Sergey Gorlatov ,  Ling Huang

    IPC分类号： C12P21/08 ,  C07K16/00 ,  C07K17/00

    CPC分类号： A61K39/39558 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/005 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734

    摘要： The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

    摘要翻译： 本发明涉及包括变体Fc区的分子，特别是多肽，更特别是免疫球蛋白（例如，抗体），其中所述变体Fc区相对于野生型Fc区包含至少一个氨基酸修饰，所述变体Fc区 相对于包含野生型Fc区的可比分子，以更高的亲和力结合FcγRIIIA和/或FcγRIIA。 本发明的分子特别可用于预防，治疗或改善与疾病，病症或感染相关的一种或多种症状。 本发明的分子特别可用于治疗或预防需要由FcγR介导的效应细胞功能增强的功效（例如ADCC）的疾病或病症，例如癌症，感染性疾病和增强治疗功效 的治疗性抗体，其作用由ADCC介导。

    LARGE-FIELD UNIT-MAGNIFICATION PROJECTION OPTICAL SYSTEM
    9.
    发明申请
    LARGE-FIELD UNIT-MAGNIFICATION PROJECTION OPTICAL SYSTEM 有权
    大型放大投影光学系统

    公开(公告)号：US20090185290A1

    公开(公告)日：2009-07-23

    申请号：US12302824

    申请日：2006-12-04

    申请人： Tiejun Li ,  Ling Huang ,  Jun Wei

    发明人： Tiejun Li ,  Ling Huang ,  Jun Wei

    IPC分类号： G02B17/08

    CPC分类号： G02B17/08 ,  G02B13/26 ,  G03F7/70225 ,  G03F7/70791

    摘要： The present invention discloses a large-field unit-magnification projection optical system. The optical system includes an optical axis, a spherical concave reflection mirror; a lens group with positive refracting power arranged adjacent the mirror with an air space therebetween. The lens group includes a first plano-convex lens, a negative meniscus lens adjacent the plano-convex lens, a positive lens adjacent the negative meniscus lens, a negative double-convex lens spaced apart far from the positive lens, and a second plano-convex lens. The optical system further includes a pair of prisms each having respective first and second surface. The second surfaces are arranged adjacent the flat surface of the plano-convex lens element on opposite sides of the optical axis and the first surfaces are arranged adjacent object planes and image planes, respectively. Each lens in the lens group and the pair of prisms provide chromatic aberration correction in a spectral region that contains at least g, h and i-line wavelengths. In this projection optical system, the object plane is parallel to the image plane.

    摘要翻译： 本发明公开了一种大视场单位放大投影光学系统。 光学系统包括光轴，球面凹面反射镜; 具有正反射功率的透镜组，其布置在反射镜附近，其间具有空气空间。 透镜组包括第一平凸透镜，与平凸透镜相邻的负弯月透镜，邻近负弯月透镜的正透镜，与正透镜间隔开的负双凸透镜，以及第二平凸透镜， 凸透镜 光学系统还包括一对棱镜，每个棱镜具有相应的第一和第二表面。 第二面与光轴的相对侧的平凸透镜元件的平面相邻配置，第一面与物平面和像面分别配置。 透镜组中的每个透镜和一对棱镜在包含至少g，h和i线波长的光谱区域中提供色差校正。 在该投影光学系统中，物平面与图像平面平行。

    Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof
    10.
    发明申请
    Fc.gamma.RIIB-Specific Antibodies and Methods of Use Thereof 有权
    Fc.gamma.RIIB特异性抗体及其使用方法

    公开(公告)号：US20080044429A1

    公开(公告)日：2008-02-21

    申请号：US11768852

    申请日：2007-06-26

    申请人： Leslie Johnson ,  Ling Huang ,  Robyn Gerena

    发明人： Leslie Johnson ,  Ling Huang ,  Robyn Gerena

    IPC分类号： A61K39/395 ,  A61P35/00 ,  C07H21/00 ,  C07K16/00 ,  C07K16/30 ,  C07K7/06 ,  C07K7/08 ,  C12N1/00 ,  C12N15/63 ,  C12P21/02

    CPC分类号： C07K16/283 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/92

    摘要： The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

    摘要翻译： 本发明涉及以比所述抗体或其片段更大的亲和力结合FcγRIIA，特别是人FcγRIIA的FcγRIIB特别是人FcγRIIB特异性结合的抗体或其片段。 本发明还提供抗FcγRIIB抗体或其抗原结合片段作为单一药物治疗用于治疗，预防，治疗或改善癌症，优选B细胞恶性肿瘤，特别是B细胞 细胞性慢性淋巴细胞白血病或非霍奇金淋巴瘤，自身免疫性疾病，炎症性疾病，IgE介导的过敏性疾病或其一种或多种症状。 本发明提供了通过施用本发明的抗体来增强治疗性抗体的效应功能来增强治疗性抗体的治疗效果的方法。 本发明还提供了通过施用本发明的抗体来增强疫苗组合物的功效的方法。